Friday, November 5th
chaired by G.Frisoni, IRCCS San Giovanni di Dio, Italy, S.Gauthier, McGill University, Canada
8.00 - 8.30 a.m
8.30 - 9.00 a.m
9.00 - 9.30 a.m
9.30 - 10.00 a.m
10.00 - 10.30 a.m
10.30 - 11.00 a.m
Autoimmune trials in AD
R.Dodel, University of Marburg, Germany
Lithium trial in AD
H.Hampel, Goethe University, Germany
Tau-focused therapies in clinical trials
S.Whitaker, Allon therapeutics, USA
Development Update on Dimebon in AD & HD
B. Winblad, Karolinska Institutet, Sweden
What we have learned from the tarenflurbil (Myriad) trials
G.Wilcock, University of Bristol, UK
Coffee Break and poster session
OTHER ASPECTS FOR CLINICAL TRIALS IN AD
11.00 - 11.20 a.m
11.20 - 11.40 a.m
11.40 - 12.00 p.m
12.00 - 12.20 p.m
12.20 - 1.20 p.m
PLASA: Results from the PLasa Study
F. Nourashemi, CHU Toulouse, France
Quality of life and clinical trials: data from the PLASA study
N.Coley, S.Andrieu, CHU Toulouse, France
Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials
for Alzheimer’s disease
H.Fillit, ADDF USA
Impact of the action of the French National Center for management of trials on health products
P.J.Ousset, CHU Toulouse, J.Touchon, CHU Montpellier, France, V.Diebolt, CENGEPS Lyon, France
Lunch Break
1.20 - 2.15 p.m ORAL COMMUNICATIONS
2.15 - 2.45 p.m
Coffee Break and poster session
2.45 - 4.00 p.m ORAL COMMUNICATIONS
ANT Congrès - 154 avenue de Lodève - 34070 Montpellier - France
E-mail : ctad@ant-congres.com
Tel : + 33 (0) 6 85 54 70 98
Fax : + 33 (0)4 67 10 92 23